1 week Ago By Defense World Staff
Bank of Montreal Can bought a new position in Agenus Inc. ( NASDAQ:AGEN – Free Report ) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 25,160 shares of the biotechnology company’s stock, valued at approximately $69,000.
Bank of Montreal Can owned 0.11% of Agenus at the end of the most recent reporting period. A number of other institutional investors and hedge funds have also recently bought and sold shares of AGEN.
Virtu Financial LLC acquired a new position in shares of Agenus during the 4th quarter worth about $51,000. Apollon Wealth Management LLC acquired a new position in shares of Agenus during the fourth quarter worth approximately $55,000. Barclays PLC boosted its position in shares of Agenus by 295.
3% in the third quarter. Barclays PLC now owns 27,813 shares of the biotechnology company’s stock valued at $152,000 after acquiring an additional 20,777 shares during the period. Geode Capital Management LLC grew its stake in shares of Agenus by 7.
1% in the third quarter. Geode Capital Management LLC now owns 483,059 shares of the biotechnology company’s stock worth $2,648,000 after acquiring an additional 32,016 shares during the last quarter. Finally, State Street Corp increased its position in Agenus by 2.
1% during the third quarter. State Street Corp now owns 467,771 shares of the biotechnology company’s stock worth $2,563,000 after acquiring an additional 9,731 shares during the period. Institutional investors and hedge funds own 61.
46% of the company’s stock. Analyst Upgrades and Downgrades Several analysts have issued reports on the stock. B.
Riley restated a “buy” rating on shares of Agenus in a research report on Monday, April 21st. StockNews.com upgraded Agenus from a “sell” rating to a “hold” rating in a research note on Friday, March 21st.
Robert W. Baird cut their price target on Agenus from $6.00 to $3.
00 and set a “neutral” rating for the company in a report on Wednesday, March 12th. Finally, HC Wainwright reissued a “neutral” rating on shares of Agenus in a report on Tuesday, March 18th. Six investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock.
Based on data from MarketBeat, Agenus has an average rating of “Hold” and an average price target of $8.75. Agenus Trading Down 4.
3 % NASDAQ AGEN opened at $2.70 on Friday. Agenus Inc.
has a 1-year low of $1.38 and a 1-year high of $19.69.
The stock’s 50 day moving average is $2.13 and its two-hundred day moving average is $3.04.
The company has a market capitalization of $68.33 million, a price-to-earnings ratio of -0.24 and a beta of 1.
58. Agenus ( NASDAQ:AGEN – Get Free Report ) last announced its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($2.
04) EPS for the quarter, beating the consensus estimate of ($2.36) by $0.32.
The company had revenue of $26.84 million during the quarter, compared to analyst estimates of $30.09 million.
On average, analysts predict that Agenus Inc. will post -12.55 earnings per share for the current year.
Agenus Profile ( Free Report ) Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. See Also Five stocks we like better than Agenus Mastering Discipline: Overcoming Emotional Challenges In Trading Markets Think Robinhood Earnings Could Send the Stock Up NYSE Stocks Give Investors a Variety of Quality Options Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Utilities Stocks Explained – How and Why to Invest in Utilities AT&T: Subscriber Growth & Buybacks Signal Bullish Turnaround Want to see what other hedge funds are holding AGEN? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Agenus Inc. ( NASDAQ:AGEN – Free Report ). Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.
com's FREE daily email newsletter ..
